Performance of the Paragit Sleeve to Measure and Monitor Motor Symptoms in Patients With Parkinson's Disease (PARPIV23)
An Open Multi-centre Investigation to Evaluate the Performance of the Paragit Sleeve With build-in sEMG Sensors, Kinetic Sensors, and Smart-textile to Measure and Monitor Motor Symptoms and Treatment-induced Dyskinesia in Patients With Parkinson's Disease
This investigation is undertaken to:
- Evaluate the accuracy and reliability of the device in measuring and recording motor symptoms associated with Parkinson's Disease (PD), and
- To assess the safety and tolerability of the device in patients with PD.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Madrid, Spain
- Recruiting
- Hospital Beata Maria Ana
-
Contact:
- Juan Pablo Romero, PhD
- Phone Number: +34
- Email: p.romero.prof@ufv.es
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Parkinson disease: Clinically diagnosed
- Age ≥ 50 (not in the childbearing aged as defined by Statistics Denmark, 15-49)
Experiencing at least two of following symptoms and/or side effect on a daily basis:
- Rigidity
- Tremor
- Bradykinesia
- Dyskinesia (treatment side effect)
Provision of informed consent, i.e., the subject must be able to:
- Read and understand the Patient Information and Consent Form
- Sign the Patient Information and Consent Form.
Exclusion Criteria:
- Known allergy/hypersensitivity to any material in direct contact with the skin (stainless steel, silicone and polyester)
- MMSE <24
- Other neurological diseases
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Paragit
Sleeve to quantify symptoms
|
Sleeve to quantify symptoms
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Tremor
Time Frame: During the clinical assessment, and for the following 24h.
|
Tremor will be assessed using the device, measured with superficial EMG [Volts], and inertial measurement unit [m/s2].
Correlation with clinical gold-standard (MDS-UPDRS) will be studied.
|
During the clinical assessment, and for the following 24h.
|
|
Bradykinesia
Time Frame: During the clinical assessment, and for the following 24h.
|
Bradykinesia will be assessed using the device, measured inertial measurement unit [m/s2].
Correlation with clinical gold-standard (MDS-UPDRS) will be studied.
|
During the clinical assessment, and for the following 24h.
|
|
Rigidity
Time Frame: During the clinical assessment, and for the following 24h.
|
The device will assess rigidity, measured with superficial EMG [Volts], and inertial measurement unit [m/s2].
Correlation with clinical gold-standard (MDS-UPDRS) will be studied.
|
During the clinical assessment, and for the following 24h.
|
|
Dyskinesia
Time Frame: During the clinical assessment, and for the following 24h.
|
The device will assess rigidity, measured with superficial EMG [Volts], and inertial measurement unit [m/s2].
Correlation with clinical gold-standard (MDS-UPDRS) will be studied.
|
During the clinical assessment, and for the following 24h.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety
Time Frame: During the clinical assessment , and for the following 24h.
|
Safety of the Paragit Sleeve by assessment of device deficiencies and adverse events, non-serious and serious, rated for causality.
|
During the clinical assessment , and for the following 24h.
|
|
Usability
Time Frame: During the clinical assessment , and for the following 24h.
|
The usability of the device will be studied using a questionnaire.
|
During the clinical assessment , and for the following 24h.
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PARPIV23
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.